• Immunome, Inc. recently reported detailed efficacy and safety data from its global Phase 3 RINGSIDE trial of varegacestat in progressing desmoid tumors, showing statistically significant improvements in progression-free survival and pain, and confirming that a New Drug Application was submitted to the US FDA in April 2026 with a European filing planned.
• An interesting aspect for investors is that the progression-free survival benefit appeared consistent across prespecified patient subgroups, suggesting varegacestat could address a broad range of patients within this rare tumor setting if approved.
• We will now examine how varegacestat’s consistent progression-free survival benefits across diverse patient subgroups may influence Immunome’s overall investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

What Is Immunome's Investment Narrative?

To own Immunome today, you have to believe that varegacestat can move from strong Phase 3 data to regulatory approvals without major surprises, while the broader pipeline justifies ongoing losses and past dilution. The latest RINGSIDE update, with consistent progression-free survival benefits across subgroups and clear pain reduction, reinforces varegacestat as the key near term catalyst and gives more substance to the NDA already filed with the FDA and the planned EMA submission. At the same time, the stock’s recent pullback, despite a very large 1 year total return and a wide gap to consensus fair value, underlines how dependent the story is on a single asset. The main risk is that Immunome remains a small revenue, loss-making biotech that may still need additional capital even if regulators take longer to decide than investors hope.

However, there is a critical regulatory timing risk here that investors should not overlook. Despite retreating, Immunome's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Two Simply Wall St Community fair value estimates span roughly US$35 to US$156 per share, reflecting very different opinions on Immunome’s potential. Set this against the concentration of risk in varegacestat and the company’s ongoing losses, and you can see why it pays to examine several viewpoints before forming your own expectations for the stock’s future performance.

Explore 2 other fair value estimates on Immunome - why the stock might be worth just $35.36!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.